GLP-1 based therapy (semaglutide/tirzepatide)
GLP-1 receptor agonist therapy uses molecules such as semaglutide and tirzepatide, available as injectable or oral formulations, to help manage type 2 diabetes and, for some patients, weight.
GLP-1 receptor agonists — semaglutide and tirzepatide — are prescription medicines used for type 2 diabetes and, for some patients, weight management. They work through the body's own gut-hormone signaling, not by "tricking" the body, and they're used alongside lifestyle measures, not instead of them. Whether one is right for you depends on an individualized assessment — this isn't a blanket or first-line recommendation for everyone with diabetes or excess weight.
Your GLP-1 therapy pathway
Assessing Suitability
We review your diabetes or weight history, other conditions, current medicines, and any contraindications together.
Choosing Molecule and Formulation
We discuss semaglutide or tirzepatide, and injectable or oral formulations, matched to your goals and preferences.
Starting Dose and Titration
Treatment begins at a low dose, increased gradually on a set schedule to reduce side effects.
Injection or Tablet Training
Hands-on teaching for your specific device or, for oral semaglutide, its particular administration steps.
Monitoring for Effect and Side Effects
We track glucose, weight, tolerability, and safety as treatment continues.
Ongoing Follow-Up and Dose Review
Your dose and regimen are reviewed and adjusted, or continued, based on your response.
Who it’s for
Patients with type 2 diabetes, and in some cases patients being evaluated for medical weight management — always via individualized, prescription-only assessment, never as a blanket recommendation.
How GLP-1 medicines work in the body
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. GLP-1 receptor agonist medicines mimic this hormone's effects, acting on several organs at once rather than through a single mechanism.
Pancreas
Helps the pancreas release more insulin when glucose is high, and less glucagon (a hormone that raises glucose)
Stomach
Slows how fast the stomach empties, which increases fullness after meals
Brain
Acts on appetite centers in the brain to reduce hunger and food cravings
Liver
Lowers how much glucose the liver releases into the bloodstream
Semaglutide vs. tirzepatide
Both are GLP-1 receptor agonists, but tirzepatide also acts on a second gut hormone receptor (GIP), which is why the two aren't interchangeable and the choice is individualized.
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | Acts on the GLP-1 receptor | Acts on both the GLP-1 receptor and the GIP receptor (dual agonist) |
| Approved use in India | Type 2 diabetes; also approved for chronic weight management | Type 2 diabetes; also approved for chronic weight management |
| Formulations | Weekly injection or daily oral tablet | Weekly injection |
| Dosing frequency | Once weekly (injection) or once daily (oral) | Once weekly |
Available in India: formulations and brand names
Molecule names are used first below; brand names are noted only for patient recognition, not as an endorsement of any manufacturer. Availability and approval status continue to evolve, so this is confirmed with you at your visit rather than assumed from this list.
- Tirzepatide (Mounjaro) was approved in India by the CDSCO in March 2025 for both type 2 diabetes and chronic weight management (adults with a BMI of 30 or more, or 27 or more with a weight-related condition), so the separate obesity brand used abroad (Zepbound) is not needed here
| Molecule | Formulation | Approved use in India | Brand names (for recognition only) |
|---|---|---|---|
| Semaglutide, injectable | Weekly injection | Type 2 diabetes | Ozempic, plus generic versions from several DCGI-approved Indian manufacturers following the molecule's 2026 patent expiry |
| Semaglutide, higher-dose injectable | Weekly injection | Chronic weight management | Wegovy — also holds a separate India approval related to fatty liver disease; see our fatty liver (MASLD/MASH) page |
| Semaglutide, oral | Daily tablet | Type 2 diabetes | Rybelsus |
| Tirzepatide, injectable | Weekly injection (vial or KwikPen) | Type 2 diabetes; chronic weight management | Mounjaro |
Who GLP-1 therapy isn't right for
GLP-1 therapy isn't suitable for everyone. Your care team confirms your individual eligibility rather than relying on a checklist alone, but some situations generally rule it out or call for particular caution.
Situations that generally rule out GLP-1 therapy
- A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Type 1 diabetes — these medicines are not a substitute for insulin in type 1 diabetes
- Pregnancy, or actively planning a pregnancy
- Severe gastrointestinal disease, such as significant gastroparesis
- A history of pancreatitis — discussed individually with your care team
Starting treatment: dose, titration, and administration
Doses start low and increase gradually on a set schedule — this titration is deliberate, and its main purpose is to reduce gastrointestinal side effects rather than to slow down the treatment's effect unnecessarily.
- Injectable formulations (semaglutide or tirzepatide) are given once weekly, with injection sites rotated between the abdomen, thigh, and upper arm
- Oral semaglutide (Rybelsus) is taken once daily, first thing in the morning, on an empty stomach, with no more than a small sip of plain water
- After taking oral semaglutide, wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines
- Don't increase your own dose faster than prescribed, even if side effects are minimal — the schedule is set for safety, not just tolerability
Common side effects and what to expect
Gastrointestinal symptoms are the most common side effects of GLP-1 therapy. They're usually most noticeable around dose increases and tend to ease as your body adjusts, though this varies between individuals.
- Nausea, the most commonly reported side effect, particularly early in treatment or after a dose increase
- Vomiting, diarrhea, or constipation
- Reduced appetite — an expected effect for many patients, though it should stay manageable rather than prevent adequate nutrition
- Mild injection-site reactions with injectable formulations
Monitoring, follow-up, and what happens if you stop
Follow-up reviews your glucose or weight trend, side effects, and whether the current dose and molecule are still the right fit — treatment isn't started once and left unchanged.
It's worth being clear about expectations: for weight managed with GLP-1 therapy, evidence consistently shows that weight tends to return after stopping the medicine unless lifestyle measures are continued — this isn't stated to discourage treatment, but so you can plan for it realistically alongside your care team.
What to expect
Your care team discusses the specific molecule, formulation, dosing, and what to expect, including common side effects and monitoring, before you start. Doses typically begin low and increase gradually.
Evidence basis
The ADA Standards of Care in Diabetes—2026 supports GLP-1 receptor agonist therapy as part of individualized glucose and weight management, chosen alongside — not instead of — nutrition, activity, and other lifestyle measures. Molecule names are used here first; brand names are noted only for patient recognition, not as an endorsement of any manufacturer.
When to seek care
- Severe abdominal pain, especially if it radiates to your back — a possible sign of pancreatitis
- Signs of a serious allergic reaction: swelling of the face, lips, or tongue, difficulty breathing, or a widespread rash
- Persistent vomiting that prevents you from keeping fluids down
- Severe pain in the upper right abdomen with fever or yellowing of the skin or eyes — a possible sign of a gallbladder problem
- A new lump or swelling in your neck, hoarseness, or difficulty swallowing
- Symptoms of low blood sugar, particularly if you also take insulin or a sulfonylurea
FAQ
What is GLP-1 therapy?
GLP-1 receptor agonist therapy uses medicines such as semaglutide and tirzepatide that mimic a natural gut hormone, helping manage blood glucose in type 2 diabetes and, for some patients, supporting weight management.
How is GLP-1 therapy different from insulin?
Insulin directly replaces or supplements the hormone your body needs to move glucose out of the bloodstream. GLP-1 therapy works differently — it stimulates your own insulin release when glucose is high, slows digestion, and reduces appetite. They're sometimes used together.
What's the difference between semaglutide and tirzepatide?
Both act on the GLP-1 receptor, but tirzepatide also acts on a second receptor (GIP), making it a dual agonist. This affects how each is used and dosed — your care team helps decide which fits your situation.
Is this a diabetes medicine or a weight-loss medicine?
Both, depending on the specific product and approved use. Semaglutide is approved in India for type 2 diabetes and, at a higher dose, for chronic weight management. Tirzepatide (Mounjaro) is approved in India for both type 2 diabetes and chronic weight management.
Is GLP-1 therapy an injection or a tablet?
Both formulations exist for semaglutide — a weekly injection or a daily oral tablet (Rybelsus) with specific administration requirements. Tirzepatide is currently available in India only as a weekly injection.
How often do I take it?
Injectable semaglutide and tirzepatide are given once weekly. Oral semaglutide is taken once daily, first thing in the morning on an empty stomach.
What if I miss a dose?
This depends on the specific formulation and how much time has passed. Ask your care team for guidance specific to your medicine rather than guessing, since the answer differs by product.
What are the common side effects?
Gastrointestinal symptoms are most common — nausea, vomiting, diarrhea, or constipation — particularly early in treatment or after a dose increase. Reduced appetite is also expected for many patients.
Do the side effects go away?
For many people, gastrointestinal side effects ease as the body adjusts, especially once a stable dose is reached. They can recur with each dose increase during titration.
Who shouldn't take GLP-1 therapy?
Generally not used with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, in type 1 diabetes, during pregnancy or when planning one, or with significant gastroparesis — confirmed individually with your care team.
Is GLP-1 therapy safe long-term?
These medicines are supported by the ADA Standards of Care as part of individualized diabetes and weight management, with ongoing monitoring built into treatment. Long-term suitability is reassessed at your follow-up visits rather than assumed indefinitely.
Will I regain weight if I stop?
Evidence consistently shows weight tends to return after stopping GLP-1 therapy unless lifestyle measures are continued. This is discussed as part of planning treatment, not just at the point of stopping.
Is generic semaglutide available in India?
Yes. Following the molecule's 2026 patent expiry, several DCGI-approved Indian manufacturers now produce generic semaglutide alongside the originator product.
What's the difference between Ozempic, Wegovy, and Rybelsus?
All three contain semaglutide. Ozempic and Rybelsus (oral) are approved for type 2 diabetes; Wegovy is a higher-dose injectable formulation approved for chronic weight management. Brand names are noted for recognition only.
Is Zepbound available in India?
Zepbound, the obesity brand of tirzepatide used abroad, is not sold in India. It isn't needed: Mounjaro (tirzepatide) was approved in India in March 2025 for both type 2 diabetes and chronic weight management.
Can I take GLP-1 therapy together with insulin?
Sometimes, depending on your individual treatment plan — this combination needs careful monitoring for low blood sugar and is managed individually with your care team.
Does GLP-1 therapy cure diabetes?
No. It's an evidence-based treatment for managing blood glucose, used alongside — not instead of — nutrition, activity, and other lifestyle measures. There's no cure claim associated with this therapy.
Medical disclaimer: Content on this page is for general education and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary between patients. Boston Diabetes Center is outpatient / day-care specialty centre with an on-site diagnostic lab and pharmacy — no inpatient beds; imaging and inpatient care are coordinated through partner facilities.